title: Delta Np73 expression in thyroid neoplasms originating from follicular cells.
abstract: OBJECTIVE
  p73, a homologue of p53, is known as a negative regulator of tumour progression. However, delta Np73, an isoform of p73 lacking the NH2-terminal transactivation domain plays an oncogenic role by interfering with the activity of p53 and TA (full-length transactivating isoforms) p73. In this study, we investigated the expression of delta Np73 in human thyroid neoplasms originating from follicular cells.
  
  
  METHODS
  We immunohistochemically investigated delta Np73 expression in 223 thyroid neoplasms. Delta Np73 expression level was evaluated as the sum of positivity score and intensity score.
  
  
  RESULTS
  Normal follicular cells did not express delta Np73, but 27.3% of follicular adenoma, 85.4% of follicular carcinoma, 99.2% of papillary carcinoma, and 95.7% of anaplastic carcinoma were positive for the transcript. Delta Np73 expression level did not differ between widely invasive and minimally invasive follicular carcinomas. In papillary carcinoma, the level was inversely linked to tumour size, extrathyroid extension, and clinically apparent metastasis. Furthermore, in anaplastic carcinoma, delta Np73 expression level was significantly lower than that in papillary carcinoma.
  
  
  CONCLUSIONS
  Our findings indicate that delta Np73 plays a role predominantly in the early phase of papillary carcinoma progression.
authors.affiliation: Department of Surgery, Kuma Hospital, Kobe, Japan. ito01@kuma-h.or.jp
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Ito
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Uramoto
authors.forename: Keiko
authors.initials: K
authors.lastname: Funa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yoshida
authors.forename: Tomoo
authors.initials: T
authors.lastname: Jikuzono
authors.forename: Shuji
authors.initials: S
authors.lastname: Asahi
authors.forename: Takuya
authors.initials: T
authors.lastname: Higashiyama
authors.forename: Chisato
authors.initials: C
authors.lastname: Tomoda
authors.forename: Yuuki
authors.initials: Y
authors.lastname: Takamura
authors.forename: Akihiro
authors.initials: A
authors.lastname: Miya
authors.forename: Kaoru
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Fumio
authors.initials: F
authors.lastname: Matsuzuka
authors.forename: Kanji
authors.initials: K
authors.lastname: Kuma
authors.forename: Akira
authors.initials: A
authors.lastname: Miyauchi
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000378:metabolism* / Q000556:secondary; D000236:Adenoma / Q000378:metabolism* / Q000473:pathology; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000378:metabolism*; D018450:Disease Progression; D006801:Humans; D007124:Immunoenzyme Techniques; D009687:Nuclear Proteins / Q000378:metabolism*; D013961:Thyroid Gland / Q000378:metabolism* / Q000473:pathology; D013964:Thyroid Neoplasms / Q000378:metabolism* / Q000473:pathology; D025521:Tumor Suppressor Proteins / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; D025521:Tumor Suppressor Proteins